Synthon

Synthon company information, Employees & Contact Information

Explore related pages

Related company profiles:

Synthon is an international, science-centered pharmaceutical company specialized in developing and manufacturing high-quality generic medicines for patients around the world. Synthon's innovative R&D and proven ability to manufacture and distribute high-quality pharmaceuticals position the company well for the future. We work to develop therapies that address the needs of people worldwide and help improve their health and well-being. Through the provision of high-quality generic medicines, we make treatments more affordable and increase access to important remedies. Currently, our products are approved by regulatory agencies in more than 90 countries and marketed through strategic partnerships and – in dedicated areas – through direct sales. Synthon’s head office is based in Nijmegen, the Netherlands, and the company has affiliates in eight other countries. Synthon employs around 1,600 staff worldwide. In 2019, the company recorded a turnover of EUR 261 million. We are interested in result-oriented people with a sharp mind and entrepreneurial spirit, who can contribute to our ambition to provide solutions to the healthcare challenges of today and tomorrow. Interested in a new step in your pharma career? We would like to get to know you! For more information, go to www.synthon.com. In case your comment to one of our posts is missing, please check out our guidelines on www.synthon.com/information/comment-missing.

Company Details

Employees
1.33K
Founded
-
Address
Microweg 22, Nijmegen,6545 Cm,netherlands
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Nijmegen
Looking for a particular Synthon employee's phone or email?

Synthon Questions

News

Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules (generic version of ZEPOSIA®) for the U.S. market - PR Newswire Canada

Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules (generic version of ZEPOSIA®) for the U.S. market PR Newswire Canada

BC Partners Nears Sale of Synthon to Goldman Sachs Asset Arm - Bloomberg.com

BC Partners Nears Sale of Synthon to Goldman Sachs Asset Arm Bloomberg.com

Goldman Sachs’ investment arm agrees €2bn deal for drugmaker Synthon - Financial Times

Goldman Sachs’ investment arm agrees €2bn deal for drugmaker Synthon Financial Times

Zydus enters into licensing and supply agreement with Synthon BV - Business Standard

Zydus enters into licensing and supply agreement with Synthon BV Business Standard

Zydus acquires Synthon BV novel cancer drug marketing rights in US - ET Pharma

Zydus acquires Synthon BV novel cancer drug marketing rights in US ET Pharma

BC Partners agrees to sell majority stake in Synthon to Goldman Sachs Alternatives - pehub.com

BC Partners agrees to sell majority stake in Synthon to Goldman Sachs Alternatives pehub.com

Relaxation of Nateglinide-Pyridinecarboxamide Coamorphous Systems to Cocrystals: Synthon Competition with Acid, Amide, and Pyridine Groups - ACS Publications

Relaxation of Nateglinide-Pyridinecarboxamide Coamorphous Systems to Cocrystals: Synthon Competition with Acid, Amide, and Pyridine Groups ACS Publications

Zydus Life shares rise 3% on licencing deal with Synthon; key details - Business Today

Zydus Life shares rise 3% on licencing deal with Synthon; key details Business Today

H-synthon enables asymmetric radical difluoroalkylation for synthesis of chiral difluoromethylated amines - Nature

H-synthon enables asymmetric radical difluoroalkylation for synthesis of chiral difluoromethylated amines Nature

Latham Advises BC Partners on Sale of Majority Stake in Synthon - Latham & Watkins LLP

Latham Advises BC Partners on Sale of Majority Stake in Synthon Latham & Watkins LLP

Ethylene as a synthon in carbonylative synthesis - ScienceDirect.com

Ethylene as a synthon in carbonylative synthesis ScienceDirect.com

Metal Vapour Synthesis of an Organometallic Barium(0) Synthon - Wiley Online Library

Metal Vapour Synthesis of an Organometallic Barium(0) Synthon Wiley Online Library

BC Partners eyes Synthon exit amid selling spree - Private Equity News

BC Partners eyes Synthon exit amid selling spree Private Equity News

Understanding the Synthon Preferences in Molecular Ionic Cocrystals of Trimethoprim─An Experimental and Computational Study - ACS Publications

Understanding the Synthon Preferences in Molecular Ionic Cocrystals of Trimethoprim─An Experimental and Computational Study ACS Publications

Facile enantioselective synthesis of multi-substituted norbornanes/norbornenes using a latent synthon strategy - Nature

Facile enantioselective synthesis of multi-substituted norbornanes/norbornenes using a latent synthon strategy Nature

Shape-Aware Synthon Search (SASS) for Virtual Screening of Synthon-Based Chemical Spaces - ACS Publications

Shape-Aware Synthon Search (SASS) for Virtual Screening of Synthon-Based Chemical Spaces ACS Publications

Synthon-based ligand discovery in virtual libraries of over 11 billion compounds - Nature

Synthon-based ligand discovery in virtual libraries of over 11 billion compounds Nature

RLSynC: Offline–Online Reinforcement Learning for Synthon Completion - ACS Publications

RLSynC: Offline–Online Reinforcement Learning for Synthon Completion ACS Publications

Tetramethylphosphinane as a new secondary phosphine synthon | Communications Chemistry - Nature

Tetramethylphosphinane as a new secondary phosphine synthon | Communications Chemistry Nature

A short peptide synthon for liquid–liquid phase separation - Nature

A short peptide synthon for liquid–liquid phase separation Nature

Goldman Unit Buys €2 Billion Drugmaker Synthon From BC Partners - Bloomberg.com

Goldman Unit Buys €2 Billion Drugmaker Synthon From BC Partners Bloomberg.com

Zydus ties up with Synthon BV for multiple sclerosis drug launch in US - The Economic Times

Zydus ties up with Synthon BV for multiple sclerosis drug launch in US The Economic Times

Netherlands: BC Partners sells stake in Synthon to Goldman Sachs Alternatives for reported US$2bn valuation - Investors in Healthcare

Netherlands: BC Partners sells stake in Synthon to Goldman Sachs Alternatives for reported US$2bn valuation Investors in Healthcare

Zydus Lifesciences shares in focus on licensing deal with Synthon for generic ZEPOSIA in US market - The Economic Times

Zydus Lifesciences shares in focus on licensing deal with Synthon for generic ZEPOSIA in US market The Economic Times

Chlorodifluoromethane as a C1 Synthon in the Assembly of N -Containing Compounds - ScienceDirect.com

Chlorodifluoromethane as a C1 Synthon in the Assembly of N -Containing Compounds ScienceDirect.com

Synthon succeeds with Brinkhof and BarentsKrans in jurisidiction claim against Teva - JUVE Patent

Synthon succeeds with Brinkhof and BarentsKrans in jurisidiction claim against Teva JUVE Patent

Zydus Lifesciences shares gain on signing licensing agreement with Synthon - Moneycontrol

Zydus Lifesciences shares gain on signing licensing agreement with Synthon Moneycontrol

Goldman Sachs set to pay €2 billion for Dutch pharma firm Synthon International - NL Times

Goldman Sachs set to pay €2 billion for Dutch pharma firm Synthon International NL Times

Acid···Amide Supramolecular Synthon in Cocrystals: From Spectroscopic Detection to Property Engineering - ACS Publications

Acid···Amide Supramolecular Synthon in Cocrystals: From Spectroscopic Detection to Property Engineering ACS Publications

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals - News-Medical

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals News-Medical

Zydus Ties Up With Synthon for MS Drug in US - Construction World India

Zydus Ties Up With Synthon for MS Drug in US Construction World India

Zydus, Synthon sign licensing and supply pact for Palbociclib Tablets for US market - Express Pharma

Zydus, Synthon sign licensing and supply pact for Palbociclib Tablets for US market Express Pharma

Zydus Lifesciences inks pact with Synthon for new cancer treatment product - Zee Business

Zydus Lifesciences inks pact with Synthon for new cancer treatment product Zee Business

Top Synthon Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant